Hodgkin disease and the role of the immune system

Pediatric Hematology and Oncology

Volumn 28, Issue 3, 2011, Pages 176-186

  Kennedy Nasser, Alana A ^a   Hanley, Patrick ^a   Bollard, Catherine M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

chemokines; cytotoxic T cells; EBV; Hodgkin disease; IDO secretion; regulatory T cells

Indexed keywords

FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; LATENT MEMBRANE PROTEIN 1; LYMPHOTOXIN; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA;

B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EPSTEIN BARR VIRUS; GENETIC PREDISPOSITION; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; NONHUMAN; REED STERNBERG CELL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE;

HODGKIN DISEASE; HUMANS; IMMUNE SYSTEM;

EID: 79952496446     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.557261     Document Type: Review

References (108)

1. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol. 1999;12:159-175.
2. Anastasi J, Bitter MA, Vardiman JW. The histopathologic diagnosis and subclassification of Hodgkin's disease. Hematol Oncol Clin North Am. 1989;3:187-204. (Pubitemid 19121823)
3. Portlock CS, Yaholom J. Hodgkin's disease. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. Philadelphia: WB Saunders; 2000:969-977.
4. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-2195.
5. Grufferman S, Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev. 1984;6:76-106. (Pubitemid 14024790)
6. Spitz MR, Sider JG, Johnson CC, et al. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst. 1986;76:235-239. (Pubitemid 16130004)
7. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91:10962-10966.
8. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program). 2003;225-247.
9. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11-18. (Pubitemid 38072555)
10. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375-382. (Pubitemid 27107262)
11. Brauninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer. 2006;118:1853-1861.
12. Weiss LM. Epstein-Barr virus and Hodgkin's disease. Curr Oncol Rep. 2000;2:199-204.
13. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107-1115. (Pubitemid 121001325)
14. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375-382. (Pubitemid 27107262)
15. Weinreb M, Day PJ, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child. 1996;74:27-31. (Pubitemid 26039949)
16. Chang KL, Albujar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood. 1993;81:496-501. (Pubitemid 23027170)
17. Ambinder RF, Browning PJ, Lorenzana I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood. 1993;81:462-467. (Pubitemid 23027165)
18. Gulley ML, Eagan PA, Quintanilla-Martinez L, et al. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood. 1994;83:1595-1602. (Pubitemid 24081574)
19. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer. 2003;107:298-302. (Pubitemid 37152914)
20. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107-1115. (Pubitemid 121001325)
21. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
22. Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk Lymphoma. 2003;44:929-935. (Pubitemid 36416988)
23. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212. (Pubitemid 30060911)
24. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969. (Pubitemid 28022832)
25. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347. (Pubitemid 26155031)
26. Mueller NE. Hodgkin's disease. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press; 1996:893-919.
27. Schlaifer D, Rigal-Huguet F, Robert A, et al. Epstein-Barr virus in familial Hodgkin's disease. Br J Haematol. 1994;88:636-638. (Pubitemid 24345119)
28. Glaser SL, Jarrett RF. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol. 1996;9:401-416. (Pubitemid 26362737)
29. Lin AY, Tucker AM. Current status of epidemiologic studies pertaining to Hodgkin's and non-Hodgkin's lymphomas. In: Canellos G, Lister T, Sklar J, eds. The Lymphomas Philadelphia. PA: WB Saunders; 1997:43-61.
30. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-viruspositive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet. 2005;365:2216-2224. (Pubitemid 40853915)
31. Bollard, CM. Hodgkin's disease: are you the type? Lancet. 2005;365:2162-2163.
32. Al Tonbary Y, Abdel-Razek N, Zaghloul H, et al. HLA class II polymorphism in Egyptian children with lymphomas. Hematology. 2004;9:139-145. (Pubitemid 38697029)
33. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer. 2003;107:298-302. (Pubitemid 37152914)
34. Harty LC, Lin AY, Goldstein AM, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood. 2002;99:690-693. (Pubitemid 34533109)
35. Voo KS, Fu T, Wang HY, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004;199:459-470. (Pubitemid 38233830)
36. Voo KS, Peng G, Guo Z, et al. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 2005;65:1577-1586. (Pubitemid 40270188)
37. Poppema S, Potters M, Visser L, Van den Berg AM. Immune escape mechanisms in Hodgkin's disease. Ann Oncol. 1998;9(Suppl 5):S21-S24. (Pubitemid 29049113)
38. Kennedy-Nasser AA, Bollard CM, Rooney CM. Adoptive immunotherapy for Hodgkin's lymphoma. Int J Hematol. 2006;83:385-390. (Pubitemid 44756787)
39. Robert NJ, Schneiderman H. Hodgkin's disease and the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:142-143. (Pubitemid 14088088)
40. Fuks Z, Strober S, Kaplan HS. Interaction between serum factors and T lymphocytes in Hodgkin's disease. use as a diagnostic test. N Engl J Med. 1976;295:1273-1278. (Pubitemid 8002876)
41. Ferraris AM, Racchi O, Rapezzi D, et al. Familial Hodgkin's disease: a disease of young adulthood? Ann Hematol. 1997;74:131-134. (Pubitemid 27182324)
42. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332:413-418.
43. Bjorkholm M, Holm G, Mellstedt H. Immunological family studies in Hodgkin's disease. Is the immunodefciency horizontally transmitted? Scand J Haematol. 1978;20:297-305. (Pubitemid 8332255)
44. Bjorkholm M, Holm G, De Faire U, Mellsted H. Immunological defects in healthy twin siblings to patients with Hodgkin's disease. Scand J Haematol. 1977;19:396-404. (Pubitemid 8211637)
45. Ricci M, Romagnani S. Immune status in Hodgkin's disease. In: Doria G, Eskol A, eds. The Immune System: Function and Terapy of Dysfunction. New York: Lipincott Williams & Wilkins; 1980:105-130.
46. Hors J, Dausset J. HLA and susceptibility to Hodgkin's disease. Immunol Rev. 1983;70:167-192. (Pubitemid 13008988)
47. Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol. 1992;66:3715-3724.
48. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994;68:7374-7385. (Pubitemid 24328793)
49. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008;49 Suppl 1:27-34.
50. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177:339-349. (Pubitemid 23117083)
51. Workman CJ, Szymczak-Workman AL, et al. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66:2603-2622.
52. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol. 2002;110:693-702. (Pubitemid 35423170)
53. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762. (Pubitemid 38268969)
54. Álvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467-1473. (Pubitemid 40315228)
55. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1 +tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009;40:1715-1722.
56. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1 +T lymphocytes coinfiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57.
57. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10:1185-1192.
58. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. (Pubitemid 351600389)
59. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762. (Pubitemid 38268969)
60. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18:423-449.
61. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250-255. (Pubitemid 32061267)
62. Gruss HJ, Pinto A, Duyster J, et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today. 1997;18:156-163. (Pubitemid 27192176)
63. Maggio E, Van den BA, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol. 2002;13(Suppl 1):52-56. (Pubitemid 34567402)
64. Kanegane H, Wakiguchi H, Kanegane C, et al. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis. 1997;176:254-257. (Pubitemid 27272878)
65. Bohlen H, Kessler M, Sextro M, et al. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000;79:110-113. (Pubitemid 30195606)
66. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999;10:433-440. (Pubitemid 29236421)
67. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today. 1994;15:19-26.
68. McKenzie AN, Culpepper JA, de Waal MR, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A. 1993;90:3735-3739. (Pubitemid 23111442)
69. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med. 1994;179:135-143. (Pubitemid 24012978)
70. Lomo J, Blomhoff HK, Jacobsen SE, et al. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood. 1997;89:4415-4424. (Pubitemid 27260252)
71. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248-250. (Pubitemid 23093630)
72. de Waal MR, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol. 1993;151:6370-6381. (Pubitemid 23340383)
73. Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol. 2001;126:267-276. (Pubitemid 34124192)
74. Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463-2470. (Pubitemid 29181176)
75. Van den BA, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol. 1999;154:1685-1691. (Pubitemid 29262850)
76. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma. 2000;38:363-371. (Pubitemid 30303670)
77. Trumper L, Jung W, Dahl G, et al. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol. 1994;5(Suppl 1):93-96. (Pubitemid 24051326)
78. Luciani MG, Stoppacciaro A, Peri G, et al. The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours. Mol Pathol. 1998;51:273-276. (Pubitemid 28480345)
79. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001;2:123-128. (Pubitemid 33707929)
80. Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463-2470. (Pubitemid 29181176)
81. Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer. 2002;98:567-572. (Pubitemid 34208558)
82. Ohshima K, Karube K, Hamasaki M, et al. Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL. Int J Cancer. 2003;106:706-712. (Pubitemid 36993394)
83. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol. 2005;206:68-75. (Pubitemid 40613436)
84. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205-1213. (Pubitemid 28189110)
85. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36. (Pubitemid 28133076)
86. Montel AH, Bochan MR, Hobbs JA, et al. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol. 1995;166:236-246. (Pubitemid 26014792)
87. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154:3806-3813.
88. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
89. Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005;105:4677-4684. (Pubitemid 40807289)
90. Bonfoco E, Stuart PM, Brunner T, et al. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity. 1998;9:711-720. (Pubitemid 28557599)
91. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
92. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligandexpressing tumor cells-a mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
93. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-1366. (Pubitemid 26391458)
94. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002;196:459-468.
95. Yoshida R, Imanishi J, Oku T, et al. Induction of pulmonary indoleamine 2, 3-dioxygenase by interferon. Proc Natl Acad Sci U S A. 1981;78:129-132. (Pubitemid 11131252)
96. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516-2522. (Pubitemid 21905800)
97. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987;41:273-280. (Pubitemid 17109654)
98. Hwu P, Du MX Lapointe R, et al. Indoleamine 2, 3-dioxygenase production by human dendriticcells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596-3599. (Pubitemid 30169812)
99. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9:1269-1274. (Pubitemid 37279849)
100. Kennedy-Nasser AA, Bollard CM, Rooney CM. Adoptive immunotherapy in Hodgkin lymphoma. Int J Hemat 2006;83:385-390.
101. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364:82-90. (Pubitemid 43120630)
102. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005;223:323-329. (Pubitemid 40719630)
103. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett. 2003;90:103-122. (Pubitemid 37548466)
104. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998. (Pubitemid 35363648)
105. Pardoll D. T cells and tumours. Nature. 2001;411:1010-1012. (Pubitemid 32612311)
106. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005. (Pubitemid 35363649)
107. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocytetumor cell interaction. Immunol Rev. 2002;188:97-113. (Pubitemid 35398868)
108. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312-319. (Pubitemid 40460560)